BEAM
Price
$17.41
Change
+$0.16 (+0.93%)
Updated
May 9 closing price
Capitalization
1.75B
93 days until earnings call
NAMS
Price
$18.37
Change
-$0.90 (-4.67%)
Updated
May 9 closing price
Capitalization
2.06B
93 days until earnings call
Ad is loading...

BEAM vs NAMS

Header iconBEAM vs NAMS Comparison
Open Charts BEAM vs NAMSBanner chart's image
Beam Therapeutics
Price$17.41
Change+$0.16 (+0.93%)
Volume$2.38M
Capitalization1.75B
NewAmsterdam Pharma
Price$18.37
Change-$0.90 (-4.67%)
Volume$974.27K
Capitalization2.06B
BEAM vs NAMS Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. NAMS commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and NAMS is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (BEAM: $17.41 vs. NAMS: $18.37)
Brand notoriety: BEAM and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 90% vs. NAMS: 95%
Market capitalization -- BEAM: $1.75B vs. NAMS: $2.06B
BEAM [@Biotechnology] is valued at $1.75B. NAMS’s [@Biotechnology] market capitalization is $2.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while NAMS’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 4 bearish.
  • NAMS’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than NAMS.

Price Growth

BEAM (@Biotechnology) experienced а -13.98% price change this week, while NAMS (@Biotechnology) price change was -8.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

NAMS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.06B) has a higher market cap than BEAM($1.75B). NAMS (-28.521) and BEAM (-29.798) have similar YTD gains . NAMS has higher annual earnings (EBITDA): -241.49M vs. BEAM (-383.98M). BEAM (851M) and NAMS (834M) have equal amount of cash in the bank . NAMS has less debt than BEAM: NAMS (448K) vs BEAM (161M). BEAM has higher revenues than NAMS: BEAM (63.5M) vs NAMS (45.6M).
BEAMNAMSBEAM / NAMS
Capitalization1.75B2.06B85%
EBITDA-383.98M-241.49M159%
Gain YTD-29.798-28.521104%
P/E RatioN/AN/A-
Revenue63.5M45.6M139%
Total Cash851M834M102%
Total Debt161M448K35,938%
TECHNICAL ANALYSIS
Technical Analysis
BEAMNAMS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
58%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
41%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
43%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 4 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCVCX10.27N/A
N/A
Transamerica Mid Cap Value Opps C
TCEPX39.45-0.02
-0.05%
Nuveen Equity Index Premier
TSPIX5.77-0.01
-0.17%
Transamerica Small Cap Growth I2
SGRKX34.14-0.10
-0.29%
Allspring Growth Admin
APSRX14.97-0.07
-0.47%
NYLI Fiera SMID Growth Class A

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-4.67%
QURE - NAMS
52%
Loosely correlated
+4.41%
CMRX - NAMS
49%
Loosely correlated
N/A
CRDF - NAMS
39%
Loosely correlated
+1.14%
AUPH - NAMS
35%
Loosely correlated
-1.36%
BEAM - NAMS
34%
Loosely correlated
+0.93%
More